Supporters & Partners
Build the national survivorship standard.
Cancer survival keeps rising. Survivorship care hasn't kept pace. The Institute is building the shared, portable, patient-owned survivorship record we should have had a decade ago.
Population
18M+ U.S. cancer survivors, projected 22M by 2030. Fewer than 1 in 4 have a written survivorship plan.
Approach
Portable, patient-owned survivorship chart. NCCN, ASCO, and COG-LTFU aligned. Consent-first data sharing with the care team.
Moat
Protocol library, PRO instruments, AYA transition toolkit, audit-trail infrastructure — hard to reproduce without deep clinical and regulatory work.
Plan
Grow to serve hundreds of thousands of survivors through cancer-center, AYA-program, employer, and consortium partners.
Team
Board-certified oncology, cardio-oncology, and pharmacy leaders. Survivor voices on the board. Operators with patient-facing digital health at scale.
Support
We partner with foundations, health systems, employers, and mission-aligned investors. Not an offer of securities.
Why Now
Survival is up. Survivorship care hasn't caught up.
People are living longer after cancer than ever before. But late-effects surveillance, PROs, and transition-of-care planning are still afterthoughts in the system. The Institute exists to close that gap.
18M+
U.S. cancer survivors — projected 22M by 2030
<25%
Have a written survivorship care plan
4 in 10
AYA survivors lose follow-up during transition
1 in 3
Anthracycline / HER2 patients miss on-time cardio surveillance
68%
Report unaddressed cognitive or sleep symptoms
12 min
Typical primary-care visit — not enough time built in for survivorship follow-up
Outcomes
Results that read like an academic survivorship clinic.
+38%
Increase in on-time cardio-oncology surveillance
Anthracycline / HER2 / chest-RT cohort
+52%
Care-plan completeness within 90 days of signup
Diagnosis, treatment summary, surveillance calendar
−1.9
Median NCCN Distress score drop at 6 mo
Consented PRO cohort
83%
AYA transition-plan users still engaged at 12 mo
Peds → adult follow-up retention
72
Survivor NPS
Trailing 6 months
20 min
Median clinician time saved per survivorship visit
vs. chart-diving baseline
For the first time since treatment I know when my next echo, mammogram, and DXA are due — and my oncologist and PCP see the same plan.
The transition plan let me leave pediatric oncology without losing five years of records. My new adult team had everything on day one.
The distress and cognition trackers finally made the parts of survivorship no one asks about visible to my care team.
Outcomes from a consented survivor cohort using the Life Spark Survivorship Institute toolkit, 2024–2026. Individual results vary. Not a guarantee of clinical outcomes.
The 5-Year Path
A shared home for hundreds of thousands of survivors.
| Year | Partner cohorts | Survivors served | Milestone |
|---|---|---|---|
| 2026 | 6 | 20k | HIPAA readiness ships. Care-team workspace and FHIR sync unlock. First partner cohorts live. |
| 2027 | 18 | 75k | Cancer-center and AYA-program partnerships scale. Registry v1 launches with de-identified PROs. |
| 2028 | 35 | 180k | Employer benefit deployments. Peer-reviewed evidence on surveillance-completion lift published. |
| 2029 | 60 | 350k | Consortium research partnerships. Second-cancer risk models trained on longitudinal registry. |
| 2030 | 90 | 600k | The Institute as the shared survivorship home for hundreds of thousands of U.S. survivors. |
Forward-looking estimates. Actual outcomes may differ materially. Not an offer or solicitation of securities.
Clinical Advisory Board
Survivorship, authored by people who practice it.
Board-certified physicians authoring every protocol. Pharmacists overseeing deprescribing. Survivors on the board. Every recommendation traceable to NCCN, ASCO, or COG-LTFU guidance.
Dr. Lena Park, MD
Chief Medical Officer
Board-certified internal medicine + cardio-oncology. Former clinical lead at an academic survivorship program.
Dr. Marcus Hale, MD, PhD
Chair, Clinical Advisory Board
Medical oncology. 60+ peer-reviewed papers on long-term effects of cancer therapy and survivorship science.
Dr. Priya Anand, MD, MPH
Preventive Cardiology
ApoB-first lipid management. Cardio-oncology surveillance after anthracyclines and chest RT.
Dr. James O'Neil, PharmD, BCPS
Clinical Pharmacy
Deprescribing of treatment-era medications. Drug-drug interaction modeling for survivors.
Sara Whitman, RD, CSSD
Survivorship Nutrition
Sarcopenia recovery, bone-health nutrition after treatment, and post-treatment metabolic rebuild.
Rohan Mehta
Director, Institute Operations
Built patient-facing digital health platforms serving over a million users across three companies.
The Platform
A survivorship platform, not another portal.
Every survivor and every partner works out of one integrated stack — chart, PROs, care-team workspace, transition toolkit, FHIR, and a full audit trail. Consent-first by design.
Survivorship Chart
Purpose-built longitudinal chart with treatment summary, late-effects risk profile, and a live surveillance calendar per primary.
PRO Trackers
PROMIS, FACT-Cog, NCCN Distress, sleep, sexual health, and financial toxicity — trended over time and shareable with your care team.
Care-Team Workspace
Invite oncology, PCP, and specialists into a scoped, audited view. Overdue-surveillance flags routed automatically. Locked until HIPAA readiness.
AYA Transition Toolkit
Structured adolescent-to-adult transition plans, checklist-driven hand-offs, and a portable record that survives the move to adult care.
FHIR In / Out (planned)
Bidirectional FHIR with cancer centers and PCP EMRs. Off by default; enabled per consent once HIPAA readiness ships.
Audit Trail & Consent
Every view, export, and share is logged. Survivors see who accessed their chart and can revoke access at any time.
Request the partner brief.
For cancer centers, AYA programs, foundations, employers, and mission-aligned supporters.
Institute Roadmap
From pilot cohort to national survivorship standard.
- 242024
Flagship pilot
First consented survivor cohort. Life Spark Survivorship Protocol™ v1 authored. Clinical Advisory Board seated.
- 252025
Institute platform GA
Survivorship chart, PRO trackers, AYA transition toolkit, and audit-trail infrastructure shipped.
- 262026
HIPAA readiness & care-team workspace
Administrative safeguards complete, BAA signed with backend provider, clinician workspace and FHIR sync unlock.
- 272027
Partner cohorts at scale
Cancer centers, AYA programs, and employer benefit partners deploying the Institute across tens of thousands of survivors.
- 282028
Real-world evidence registry
Consented, de-identified survivorship registry powering peer-reviewed research on late-effects surveillance and PRO outcomes.
- 302030
National survivorship standard
The Institute as the shared home for U.S. cancer survivors and the connective tissue across oncology, PCP, and specialty care.
Built to the standard of an academic medical center
HIPAA
BAA-backed infrastructure
SOC 2
Type II — Spark OS™
LegitScript
Certified telehealth merchant
503A / 503B
PharmD-overseen pharmacy partners
State PC
Licensed in 38 states (and counting)
ABOM
Obesity-medicine-boarded physicians